Roche: experimental drug shows improvement in SMA
(CercleFinance.com) - An experimental drug from Roche showed significant improvement in motor function in people with spinal muscular atrophy, the Swiss drugmaker said on Thursday.
Roche today presented one-year data from a pivotal study evaluating risdiplam in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy.
The study showed that change from baseline in the primary endpoint of the motor function measure scale was significantly greater in people treated with risdiplam, compared to placebo, the company said.
Importantly, disease stabilisation was observed in the 18-25 year age group, which is the goal of treatment for those with more established disease.
Roche said it was "very encouraged by the positive results." For the record, the US Food and Drug Administration is set to make a decision for this drug's approval by the end of May.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Roche today presented one-year data from a pivotal study evaluating risdiplam in people aged 2-25 years with Type 2 or 3 spinal muscular atrophy.
The study showed that change from baseline in the primary endpoint of the motor function measure scale was significantly greater in people treated with risdiplam, compared to placebo, the company said.
Importantly, disease stabilisation was observed in the 18-25 year age group, which is the goal of treatment for those with more established disease.
Roche said it was "very encouraged by the positive results." For the record, the US Food and Drug Administration is set to make a decision for this drug's approval by the end of May.
Copyright (c) 2020 CercleFinance.com. All rights reserved.